BARCELONA, Spain--(BUSINESS WIRE)--Targanta Therapeutics Corporation (NASDAQ: TARG) today announced the presentation of data further detailing the in vivo and in vitro activity of its lead intravenous antibiotic candidate, oritavancin, at the 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) taking place in Barcelona, Spain, April 19th through the 22nd. Oritavancin is currently awaiting U.S. regulatory approval for the treatment of complicated skin and skin structure infections (cSSSI) caused by gram-positive bacteria, including methicillin-resistant Staphylococcus aureus, or MRSA.
